Please login to the form below

Not currently logged in
Email:
Password:

Amgen sets premium price for Blincyto

Leukaemia drug becomes one of the most expensive pharma products on the market

Amgen flag 

Amgen's newly approved Blincyto for a rare form of leukaemia will cost $178,000 per two-cycle course, making it one of the most costly drugs on the market.

The price tag looks likely to add fire to the debate about how health systems can afford to look after patients with orphan diseases, particularly in cancer which has seen a slew of new immunotherapies for highly-targeted patient populations reach the market in recent years with price tags upwards of $100,000 a year.

Amgen secured approval from the FDA for Blincyto (blinatumomab) earlier this month as a second-line treatment for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia, which affects around 6,000 patients in the US.

In trials patients received two cycles of Blincyto therapy, and the drug's label indicates that they could receive up to three more cycles. Blincyto is due to be launched in the US - its first market - today.

The drug - the first anti-CD19 drug to be approved by the FDA and also the lead candidate in Amgen's bispecific T cell engager (BiTE) antibody programme - had previously been awarded breakthrough status and a priority review for that indication.

Amgen said in a statement: "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system, for an ultra-orphan population with a dramatic impact on a serious illness."

The company added that the price also reflects "the complexity of developing, manufacturing and reliably supplying innovative biologic medicines and local pricing, reimbursement and purchasing conditions and requirements."

Analyst Michael Yee of RBC Capital Markets told Reuters that - assuming a 50% take-up for Blincyto - Amgen will make around $100m a year from the drug in ALL, although that could increase if it gets approved in additional indications, such as first-line therapy of ALL and relapsed non-Hodgkin's Lymphoma (NHL).

Other analysts have suggested it could make as much as $500m a year at peak.

Article by
Phil Taylor

18th December 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...

Infographics